Patent intelligence · US
US 11007171
Treatment and prevention of joint disorders
Treatment and prevention of joint disorders
Patent details — US 11007171
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2021
- Expiration
- May 13, 2041
- Applicant
- Summit Innovation Labs LLC
- Claims
- 11
- CPC classes
- A61K, A61K2300/00, A61K31/047, A61K31/05
Quick answer
US 11007171 (Treatment and prevention of joint disorders) is held by Summit Innovation Labs LLC. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Summit Innovation Labs LLC
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K2300/00, A61K31/047, A61K31/05, A61K31/12, A61K31/353
More from Summit Innovation Labs LLC
Related pharmaceutical patents in our USPTO index.
-
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 11344575
Vascular calcification prevention and treatment
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9314456
Antibacterial compounds
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Frequently asked questions
What is US patent 11007171?
US 11007171 (Treatment and prevention of joint disorders) is held by Summit Innovation Labs LLC. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11007171?
Summit Innovation Labs LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 11007171 expire?
Our index shows an expiration date of May 13, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.